5471-81-8

Basic information

• Product Name: METHYL 4-IODO-3-METHYLBENZOATE
• Synonyms: METHYL 4-IODO-3-METHYLBENZOATE;METHYL 4-IODO-M-TOLUATE;4-IODO-3-METHYLBENZOIC ACID METHYL ESTER;4-IODO-M-TOLUIC ACID METHYL ESTER;4-Iodo-m-toluic Acid Methyl Ester 4-Iodo-3-methylbenzoic Acid Methyl Ester Methyl 4-Iodo-m-toluate;2-Iodo-5-(methoxycarbonyl)toluene, Methyl 4-iodo-m-toluate
• CAS NO: 5471-81-8
• Molecular Formula: C₉H₉IO₂
• Molecular Weight: 276.07
• Product Categories: Aromatic Esters;Acids & Esters;Iodine Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 5471-81-8.mol

Chemical Properties

• Melting Point: 59-62°C
• Boiling Point: 106 °C / 4mmHg
• Flash Point: 134.6 °C
• Appearance: /
• Density: 1.666 g/cm³
• Vapor Pressure: 0.00123mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Slightly soluble in methanol.
• Sensitive: Light Sensitive
• CAS DataBase Reference: METHYL 4-IODO-3-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-IODO-3-METHYLBENZOATE(5471-81-8)
• EPA Substance Registry System: METHYL 4-IODO-3-METHYLBENZOATE(5471-81-8)

Safety Data

• Statements: 36/37/38
• Safety Statements: 24/25-37-26
• Hazardous Substances Data: 5471-81-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4-IODO-3-METHYLBENZOATE is used as a key intermediate in the synthesis of novel colchicine-derived nitrate esters. These esters are known for their immunosuppressant properties and are being developed as potential therapeutic agents for various medical conditions.
METHYL 4-IODO-3-METHYLBENZOATE is used as a precursor for the development of colchicine-derived nitrate esters, which exhibit immunosuppressant activity. This application is particularly relevant in the pharmaceutical industry, where these compounds may be utilized to treat autoimmune diseases and other conditions requiring immunosuppression.

InChI:InChI=1/C9H9IO2/c1-6-5-7(9(11)12-2)3-4-8(6)10/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 52107-87-6 4-iodo-3-methylbenzoic acid 
• 18595-14-7 methyl 4-amino-3-methylbenzoate 

Downstream Products

• 879288-19-4 4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methylbenzoic acid methyl ester 
• 879288-18-3 4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methylbenzoic acid methyl ester 
• 24078-24-8 methyl 4-formyl-3-methylbenzoate 
• 158429-38-0 (4-(methoxycarbonyl)-2-methylphenyl)boronic acid 
• 957205-72-0 3-Methyl-4-trifluoromethylbenzoic acid methyl ester 
• 1127737-38-5 methyl 4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenyl)ethynyl)-3-methylbenzoate 
• 1057977-05-5 4,4'-(1,2-ethynediyl)bis(3-methylbenzoic acid) dimethyl ester 
• 1080564-14-2 5-[4-(methoxycarbonyl)-2-methylphenyl]-7-methyl-4,5-dihydrobenzo[b]oxepin-2(3H)-one 
• 1192547-79-7 methyl 3'-fluoro-2-methyl-2'-(trifluoromethyl)biphenyl-4-carboxylate 
• 892843-59-3 2-methyl-biphenyl-4-carboxylic acid methyl ester 
• 25978-68-1 methyl 4-cyano-3-methylbenzoate 
• 1465295-72-0 methyl 4-((4aR,5S,10bR)-3,4,4a,5,6,10b-hexahydro-9-methoxy-2H-pyrano[3,2-c]quinolin-5-yl)-3-methylbenzoate 
• 1465295-73-1 methyl 4-((4aS,5R,10bS)-3,4,4a,5,6,10b-hexahydro-9-methoxy-2H-pyrano[3,2-c]quinolin-5-yl)-3-methylbenzoate 
• 1465295-84-4 4-((4aR,5S,10bR)-3,4,4a,5,6,10b-hexahydro-9-methoxy-2H pyrano[3,2-c]quinolin-5-yl)-3-methylbenzoic acid 

Relevant articles and documents

Palladium-Catalyzed Norbornene-Mediated Tandem Amination/Cyanation Reaction: A Method for the Synthesis of ortho-Aminated Benzonitriles

A palladium-catalyzed, norbornene-mediated tandem amination/cyanation reaction via Catellani-type C-H functionalization was developed using N-benzoyloxyamines as the amination reagent and Zn(CN)2 as the terminating agent. This transformation, in which one C-N bond and one C-C bond are formed, provides an efficient approach for the synthesis of ortho-aminated benzonitriles in one pot from easily accessible starting materials.

One-pot palladium-catalyzed synthesis of selectively substituted phenanthridines by sequential aryl-aryl and heck couplings, aza-michael and retro-mannich reactions

A catalytic synthesis of selectively substituted phenanthridines is achieved through a reaction sequence involving palladium/norbornene-catalyzed unsymmetrical aryl-aryl and Heck couplings followed by aza-Michael and retro-Mannich reactions. In spite of the many steps involved the method is very simple and allows the formation of selectively substituted phenanthridines under mild conditions in a straightforward one-pot reaction starting from readily available aryl iodides and bromides.

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

Preparation of annulated nitrogen-containing heterocycles via a one-pot palladium-catalyzed alkylation/direct arylation sequence

A palladium-catalyzed/norbornene-mediated sequential coupling reaction involving an aromatic sp2 C-H functionalization as the key step is described, in which an alkyl-aryl bond and an aryl-heteroaryl bond are formed in one pot. A variety of hig

Palladium-catalyzed sequential alkylation-alkenylation reactions. Application to the synthesis of 2-substituted-4-benzoxepines and 2,5-disubstituted-4-benzoxepines

The synthesis of 2-substituted-4-benzoxepines and 2,5-disubstituted-4-benzoxepines from aryl iodides and bromoenoates is described. This methodology is based on a palladium-catalyzed aromatic substitution followed by an intramolecular Heck sequence. Under

RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof

Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds having the structural formula (I): wherein Ar is a radical having one of the formulae (a)-(e): which are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders are provided. In particular, based on their RXR-agonist activity, these compounds may be used to treat noninsulin-dependent diabetes mellitus (NIDDM) and obesity.

Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polyaromatic propynyl compounds have the structural formula (1): STR1 in which X is one of the radicals: STR2 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds have the structural formula (I): STR1 wherein Ar is a radical having one of the formulae (a)-(i): STR2 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.